Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 9, 2015, Pages 15173-15181

  Wu, Chongyang ^a   Wu, Xiangyang ^a   Zhang, Xiaoni ^b   Chai, Ye ^a   Guo, Qi ^a   Li, Lijuan ^a   Yue, Lingling ^a   Bai, Jun ^a   Wang, Zhiping ^a   Zhang, Liansheng ^a  

^a LANZHOU UNIVERSITY   (China)

^b 1st Renmin Hospital of Lanzhou   (China)

Author keywords

Diffuse large B cell lymphoma; Monocyte; Monocytic myeloid derived suppressor cell; Revised international prognostic index

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; MONOCYTE PERCENTAGE; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL PERCENTAGE; PARAMETERS; PROGNOSIS; RISK FACTOR; SUPPRESSOR CELL;

EID: 84946552272     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Habermann T. New developments in the management of diffuse large B-cell lymphoma. Hematology 2012; 17 Suppl 1: S93-7.
2. Swerdlow SH, Campo E, Jaffe ES. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2010. pp. 233.
3. Goldman LS, Andrew I. Goldman's Cecil Medicine. 24th edition. 2012. pp. 1222.
4. Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2011; 118: 4173-4183.
5. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
6. Sehn L, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.
7. Porrata L, Ristow K, Habermann T, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/ monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 19: 19.
8. Wilcox R, Ristow K, Habermann T, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-Bcell lymphoma. Leukemia 2011; 25: 1502-1509.
9. Luis FP, Kay R, Joseph PC, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/ monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012; 97: 262-269.
10. Favaloro J, Liyadipitiya T, Brown R, Yang S, Suen H, Woodland N, Nassif N, Hart D, Fromm P, Weatherburn C, Gibson J, Ho PJ, Joshua D. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma 2014; 12: 1-8.
11. Nagaraj S, Gabrilovich D. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16: 348-353.
12. Gabrilovich D, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268.
13. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P. Identification of a CD11b (+)/Gr-1(+)/CD31 (+) myeloid progenitor capable of activating or suppressing CD8 (+) T cells. Blood 2000; 96: 3838-3846.
14. Lin Y, Gustafson M, Bulur P, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/-monocytes in B-cell non-Hodgkin lymphoma. Blood 2011; 117: 872-881.
15. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
16. Li Z, Huang J, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012; 7: 23.
17. Porrata L, Inwards D, Ansell S, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Newonset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma. Biol Blood Marrow Transplant 2010; 16: 376-383.
18. Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2011; 118: 4173-4183.
19. Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2012; 2012: 402-409.
20. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Mate JL, Sancho JM, Arenillas L, Serrano S, Escoda L, Martínez S, Valera A, Martínez A, Jares P, Pinyol M, García-Herrera A, Martínez-Trillos A, Giné E, Villamor N, Campo E, Colomo L, López-Guillermo A; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB). Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117: 4836-4843.
21. De Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Hagenbeek A, Horning S, Lister A, Raemaekers J, Salles G, Gascoyne RD, Weller E. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2008; 62: 128-138.